64 related articles for article (PubMed ID: 15939802)
21. Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.
Maida Y; Masutomi K
Cancer Sci; 2015 Nov; 106(11):1486-92. PubMed ID: 26331588
[TBL] [Abstract][Full Text] [Related]
22. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
23. Role of miR-155 in drug resistance of breast cancer.
Yu DD; Lv MM; Chen WX; Zhong SL; Zhang XH; Chen L; Ma TF; Tang JH; Zhao JH
Tumour Biol; 2015 Mar; 36(3):1395-401. PubMed ID: 25744731
[TBL] [Abstract][Full Text] [Related]
24. Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
Shawi M; Chu TW; Martinez-Marignac V; Yu Y; Gryaznov SM; Johnston JB; Lees-Miller SP; Assouline SE; Autexier C; Aloyz R
PLoS One; 2013; 8(7):e70428. PubMed ID: 23922990
[TBL] [Abstract][Full Text] [Related]
25. Telomerase as a useful target in cancer fighting-the breast cancer case.
Holysz H; Lipinska N; Paszel-Jaworska A; Rubis B
Tumour Biol; 2013 Jun; 34(3):1371-80. PubMed ID: 23558965
[TBL] [Abstract][Full Text] [Related]
26. A yeast chemical genetic screen identifies inhibitors of human telomerase.
Wong LH; Unciti-Broceta A; Spitzer M; White R; Tyers M; Harrington L
Chem Biol; 2013 Mar; 20(3):333-40. PubMed ID: 23521791
[TBL] [Abstract][Full Text] [Related]
27. Expression of (NES-)hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stress.
Kovalenko OA; Kaplunov J; Herbig U; Detoledo S; Azzam EI; Santos JH
PLoS One; 2010 May; 5(5):e10812. PubMed ID: 20520826
[TBL] [Abstract][Full Text] [Related]
28. From bench to bedside: the growing use of translational research in cancer medicine.
Goldblatt EM; Lee WH
Am J Transl Res; 2010 Jan; 2(1):1-18. PubMed ID: 20182579
[TBL] [Abstract][Full Text] [Related]
29. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.
Uziel O; Beery E; Dronichev V; Samocha K; Gryaznov S; Weiss L; Slavin S; Kushnir M; Nordenberg Y; Rabinowitz C; Rinkevich B; Zehavi T; Lahav M
PLoS One; 2010 Feb; 5(2):e9132. PubMed ID: 20161752
[TBL] [Abstract][Full Text] [Related]
30. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
Li Y; Malaeb BS; Li ZZ; Thompson MG; Chen Z; Corey DR; Hsieh JT; Shay JW; Koeneman KS
Prostate; 2010 May; 70(6):616-29. PubMed ID: 20043297
[TBL] [Abstract][Full Text] [Related]
31. Isothiocyanates sensitize the effect of chemotherapeutic drugs via modulation of protein kinase C and telomerase in cervical cancer cells.
Mukherjee S; Dey S; Bhattacharya RK; Roy M
Mol Cell Biochem; 2009 Oct; 330(1-2):9-22. PubMed ID: 19363674
[TBL] [Abstract][Full Text] [Related]
32. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
33. Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response.
Murillo-Ortiz B; Astudillo-De la Vega H; Castillo-Medina S; Malacara JM; Benitez-Bribiesca L
BMC Cancer; 2006 Aug; 6():206. PubMed ID: 16911782
[TBL] [Abstract][Full Text] [Related]
34. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
35. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
El Daly H; Martens UM
Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
[TBL] [Abstract][Full Text] [Related]
36. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.
Meng E; Taylor B; Ray A; Shevde LA; Rocconi RP
Gynecol Oncol; 2012 Mar; 124(3):598-605. PubMed ID: 22115853
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
38. Telomerase as an anti-cancer drug target: will it fulfil its early promise?
Newbold RF
Anticancer Drug Des; 1999 Aug; 14(4):349-54. PubMed ID: 10625927
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
Ward RJ; Autexier C
Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
